M&A · Healthcare · Biological Products, (No Diagnostic Substances)
Carlyle and SK Capital Partners to acquire bluebird bio, Inc.
Announced Feb 21, 2025 · Closed Jun 2, 2025
Deal value—
Premium—To unaffected price
EV / Adj. EBITDA—
ConsiderationAll cash
Transaction
- Acquirer
- Carlyle and SK Capital Partners
- Target
- bluebird bio, Inc. (BLUE)
- Buyer type
- Private equity
- Offer price per share
- —
- Enterprise value
- —
- Status
- Closed Jun 2, 2025
Deal protections
- Break fee (target pays)
- $1.5M
- Reverse fee (buyer pays)
- $2.0M
- Go-shop
- No-shop
- Financing
- —
Advisors
- To the acquirer
- Not disclosed
- To the target
- Leerink Partners
Sector context · Healthcare
- Comparable deals
- 92 in the prior 24 months
- Premium
- Sector median 65.0%
- EV / Adj. EBITDA
- Sector median 13.8x
- Break fee
- Sector median 3.4%
Timeline
- AnnouncedFeb 21, 2025
- Tender offerMar 7, 2025
- ClosedJun 2, 2025